Other News To Note
Friday, September 28, 2012
Discovery Laboratories Inc., of Warrington, Pa., began four research projects with its KL4 sufractant technology for acute lung injury. The preclinical studies will be in collaboration with research institutions, and funded through U.S. government-sponsored biodefense initiatives.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.